Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase
KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the
XUZHOU, China, March 3, 2025 /PRNewswire/ — XCMG Machinery (“XCMG”, SHE: 000425), a leading global construction machinery manufacturer, has proudly announced that three of its factories, specialized for road machinery, firefighting equipment and automotive products, have been officially included in China’s 2024 National Green Factory List, a prestigious recognition from the Ministry of Industry and
Innofactor Plc Financial Statements Bulletin February 28, 2025, at 9:00 a.m. Finnish time Key figures of the group, IFRS . Jul 1-Dec 31, 2024 Jul 1-Dec 31, 2023 Change Jan 1-Dec 31, 2024 Jan 1-Dec 31, 2023 Change Net sales, EUR thousand 36,525 39,945 -8.6% 77,576 80,263 -3.3% Growth of net sales -8.6%
– Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 – Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 – Petosemtamab
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – -The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week
Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial Continues to Progress Across Multiple Cohorts; Data in Melanoma and Colorectal Cancer Expected in Second Half of 2025 Cash, Cash Equivalents and Marketable Securities of $267.3 million
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in
Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-2025 Positive update from Phase 1b trial of DISC-0974 in patients with anemia of myelofibrosis (MF) presented at ASH 2024; initial data from ongoing Phase 2 expected in H2 2025
NORTHVILLE, Mich., Feb. 13, 2025 /PRNewswire/ — Cooper-Standard Holdings Inc. (NYSE: CPS) today reported results for the fourth quarter and full year 2024. Fourth Quarter 2024 Summary Sales totaled $660.8 million, a decrease of 1.9% vs. the fourth quarter 2023 Operating income totaled $31.7 million, an increase of $36.2 million vs. the fourth quarter of